Nektar Therapeutics (NASDAQ:NKTR) CEO Howard W. Robin sold 43,334 shares of the business’s stock in a transaction dated Monday, June 25th. The shares were sold at an average price of $51.82, for a total transaction of $2,245,567.88. Following the transaction, the chief executive officer now directly owns 267,690 shares in the company, valued at approximately $13,871,695.80. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
NASDAQ NKTR opened at $48.83 on Friday. Nektar Therapeutics has a 12 month low of $17.51 and a 12 month high of $111.36. The company has a debt-to-equity ratio of 4.21, a quick ratio of 4.03 and a current ratio of 4.16. The stock has a market capitalization of $7.93 billion, a price-to-earnings ratio of -88.78 and a beta of 1.81.
Nektar Therapeutics (NASDAQ:NKTR) last posted its earnings results on Thursday, May 10th. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.52) by ($0.08). Nektar Therapeutics had a negative net margin of 40.07% and a negative return on equity of 202.41%. The company had revenue of $38.02 million during the quarter, compared to analyst estimates of $35.59 million. During the same period in the previous year, the company earned ($0.42) EPS. The company’s quarterly revenue was up 53.7% compared to the same quarter last year. analysts predict that Nektar Therapeutics will post 3.38 EPS for the current fiscal year.
Several research analysts have recently weighed in on the stock. BidaskClub cut shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday. ValuEngine cut shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday. HC Wainwright cut shares of Nektar Therapeutics from a “buy” rating to a “neutral” rating and set a $54.00 price target on the stock. in a research report on Monday, June 11th. William Blair reissued a “buy” rating on shares of Nektar Therapeutics in a research report on Monday, June 4th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Nektar Therapeutics from $90.00 to $78.00 and set an “overweight” rating on the stock in a research report on Monday, June 4th. Five investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $76.42.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Asset Management One Co. Ltd. purchased a new stake in Nektar Therapeutics during the first quarter worth about $110,000. Daiwa Securities Group Inc. purchased a new stake in Nektar Therapeutics during the first quarter worth about $111,000. We Are One Seven LLC purchased a new stake in Nektar Therapeutics during the first quarter worth about $118,000. BB&T Investment Services Inc. purchased a new stake in Nektar Therapeutics during the fourth quarter worth about $119,000. Finally, Harbor Advisors LLC purchased a new stake in Nektar Therapeutics during the first quarter worth about $213,000. 90.76% of the stock is currently owned by institutional investors.
Nektar Therapeutics Company Profile
Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain based on its PEGylation and polymer conjugate technology platforms in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.